Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have received an average recommendation of “Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the […]
E Fund Management Co. Ltd. raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 45.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,438 shares of the biopharmaceutical company’s stock after buying an additional 12,059 shares during the quarter. E […]
Juncture Wealth Strategies LLC lessened its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,474 shares of the biopharmaceutical company’s stock after selling 908 shares during the quarter. Juncture Wealth Strategies LLC’s holdings in Catalyst […]
StockNews.com cut shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) from a strong-buy rating to a buy rating in a research note published on Tuesday morning. A number of other research firms have also recently commented on CPRX. Cantor Fitzgerald upped their target price on Catalyst Pharmaceuticals from $22.00 to $25.00 in a research note […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.